Tirzepatide (SURMOUNT-1) In adults with overweight or obesity (without type 2 diabetes), average weight loss over 72 weeks was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg), compared with 3.1% for placebo, alongside lifestyle changes
Potassium Dihydrogen Phosphate
With insurance, those drugs cost about the same as a typical meal at a restaurant which sounds less appealing on those appetite-suppressing drugs anyway
A board-certified physician reviews your health history and goals
Employer health plans and ACA insurers that have opted to cover GLP1 drugs have largely adopted cost containment measures such as prior authorization, step therapy, mandatory lifestyle programs and formulary exclusions to manage the financial impact
Obesity & Weight Management: Trials and models report meaningful weight loss and appetite reduction with GLP-1 receptor agonism, including changes in caloric intake and food preference